# Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

> **NCT03860935** · PHASE3 · COMPLETED · sponsor: **Eidos Therapeutics, a BridgeBio company** · enrollment: 632 (actual)

## Conditions studied

- Amyloidosis
- Amyloid Cardiomyopathy
- Transthyretin Amyloidosis
- Cardiomyopathies
- Heart Diseases

## Interventions

- **DRUG:** acoramidis
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03860935
- **Lead sponsor:** Eidos Therapeutics, a BridgeBio company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-19
- **Primary completion:** 2023-05-11
- **Final completion:** 2023-05-11
- **Target enrollment:** 632 (ACTUAL)
- **Last updated:** 2024-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03860935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03860935, "Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03860935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*